A big problem for guys that is not talked about enough. Hopefully.
There may be a "promising new strategy" in combating aggressive forms of prostate cancer, according to a new study.
Researchers at Flinders University and the University of South Australia investigated how the novel drug, CDKI-73, has the potential to tackle drug-resistant prostate cancer.
This drug reportedly "defies conventional therapies," as noted in the study findings, which were published in the British Journal of Cancer.
Prostate cancer is the second-leading cause of cancer death in American men, following lung cancer, according to the American Cancer Society (ACS).
In 2024, around 299,010 new cases will be diagnosed and more than 35,000 men will die from the disease, per the ACS.
The disease "frequently evolves into aggressive forms that do not respond to standard hormone therapies," according to Flinders University.
The researchers, including professors Luke Selth and Shudong Wang, targeted cyclin-dependent kinase 9 (CDK9) – a protein responsible for the growth and survival of prostate cancer cells.
Selth, of Flinders University, confirmed in a press release that the CDKI-73 inhibitor has shown to be effective in blocking prostate cancer growth in models and tumor samples.
"Our research demonstrates that CDKI-73 potently blocks the growth of prostate cancer, even aggressive subtypes of the disease that are resistant to current treatments," he said.
"Importantly, CDKI-73 targets cancer cells specifically without harming normal cells."
In an email sent to Fox News Digital, Selth said the drug is orally available as a tablet, which could help "facilitate its use as a new treatment."
Selth said he considers the study results a "significant step forward in understanding the role of CDK9 in aggressive prostate cancer."
"Having said that, we still need to do a lot more work to fully understand the potential of CDK9 inhibitors and to deliver a new treatment for patients," he added.
Wang, who developed CDKI-73, said in the release that the drug is a "promising candidate for treating solid tumors, such as prostate cancer."
"Our proof-of-principle study is an important step toward future clinical trials, and these findings will inform future studies on the use and efficacy of CDKI-73 as a prostate cancer treatment," he went on.
www.foxnews.com
There may be a "promising new strategy" in combating aggressive forms of prostate cancer, according to a new study.
Researchers at Flinders University and the University of South Australia investigated how the novel drug, CDKI-73, has the potential to tackle drug-resistant prostate cancer.
This drug reportedly "defies conventional therapies," as noted in the study findings, which were published in the British Journal of Cancer.
Prostate cancer is the second-leading cause of cancer death in American men, following lung cancer, according to the American Cancer Society (ACS).
In 2024, around 299,010 new cases will be diagnosed and more than 35,000 men will die from the disease, per the ACS.
The disease "frequently evolves into aggressive forms that do not respond to standard hormone therapies," according to Flinders University.
The researchers, including professors Luke Selth and Shudong Wang, targeted cyclin-dependent kinase 9 (CDK9) – a protein responsible for the growth and survival of prostate cancer cells.
Selth, of Flinders University, confirmed in a press release that the CDKI-73 inhibitor has shown to be effective in blocking prostate cancer growth in models and tumor samples.
"Our research demonstrates that CDKI-73 potently blocks the growth of prostate cancer, even aggressive subtypes of the disease that are resistant to current treatments," he said.
"Importantly, CDKI-73 targets cancer cells specifically without harming normal cells."
In an email sent to Fox News Digital, Selth said the drug is orally available as a tablet, which could help "facilitate its use as a new treatment."
Selth said he considers the study results a "significant step forward in understanding the role of CDK9 in aggressive prostate cancer."
"Having said that, we still need to do a lot more work to fully understand the potential of CDK9 inhibitors and to deliver a new treatment for patients," he added.
Wang, who developed CDKI-73, said in the release that the drug is a "promising candidate for treating solid tumors, such as prostate cancer."
"Our proof-of-principle study is an important step toward future clinical trials, and these findings will inform future studies on the use and efficacy of CDKI-73 as a prostate cancer treatment," he went on.
New prostate cancer medication 'shows promise' in treating aggressive disease, study finds
A new study has identified a potential breakthrough treatment to combat aggressive forms of prostate cancer. Researcher Luke Selth reacts to the findings.
www.foxnews.com
